Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. April 2017 18:48 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces First Quarter 2017 Results

TORONTO, April 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
10. April 2017 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone

TORONTO, April 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
16. März 2017 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”

TORONTO, March 16, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
24. Februar 2017 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR

TORONTO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
10. Februar 2017 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
02. Februar 2017 17:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
06. Januar 2017 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
29. Dezember 2016 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the Biotech Showcase™

TORONTO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
21. Dezember 2016 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology

TORONTO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
29. November 2016 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the LD Micro Main Event

TORONTO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...

Vorherige Seite

Nächste Seite